A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.
Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 design and enrollment target provide the first detailed view of the pivotal study, a key step toward regulatory approval.
Market read
First‑time detailed Phase 3 information for an oral osteoporosis therapy, a potentially transformative product in a large market.
What to watch
The partnership with OPKO for hypoparathyroidism and other pipeline programs may dilute focus on EB613.
Background
Entera Bio is a clinical‑stage company developing oral peptide therapeutics, with EB613 as its lead osteoporosis candidate.
Ticker impact
Entera Bio announced its Phase 3 osteoporosis trial design and enrollment target of ~900 women, with first site activation planned for late 2026.
likely upward pressure as investors price in potential approval pathway.
New Phase 3 data and FDA acceptance are material catalysts for a clinical‑stage biotech.
Market effects
Advances in oral peptide therapy could boost the broader biotech and osteoporosis treatment sectors.
US biotech investors may see increased interest in oral peptide platforms.
Potential global impact if oral osteoporosis therapy proves effective.
Counterpoint
If the Phase 3 trial faces enrollment delays or safety issues, the stock could face downside pressure.
Key entities
- companyEntera Bio Ltd.
Developer of oral peptide drugs, ticker ENTX.
- partnerOPKO Health
Collaborator on EB612 hypoparathyroidism program.


